The Charcot-Marie-Tooth Association (CMTA) announced today that it has entered into a collaboration with Affectis Pharmaceuticals AG to evaluate the efficacy of advanced Affectis compounds in neurological and behavioral models of CMT1A.
Glenolden, Pennsylvania - Affectis is a therapy development company and since 2013 a fully owned subsidiary of the Lead Discovery Center GmbH (LDC), a ...
Satisfied Users & 
Approved Press Releases
